Acuta Capital Sells Majority Stake in Ocular Therapeutix

In Q1 2026, Acuta Capital Partners reduced its stake in Ocular Therapeutix by selling 460,887 shares. The firm now holds approximately 3.5% of the fund's AUM in OCUL stock following this transaction.

By Lawrence Rothman, CFA, The Motley Fool Wed, May 27, 2026 at 1:26 AM GMT+3 3 min read · Yahoo Finance · May 26, 2026, 22:26 UTC

Acuta Capital Sells Majority Stake in Ocular Therapeutix

Tickers: $OCUL

Topics: portfolio changes SEC filing stock trading

Read the full article at Yahoo Finance

More World news

Apple to Update HomeView Software Following Feedback on Voice Command Limitations The Verge · November 12, 2026, 16:53 UTC
Endeavour Mining Shares Drop Following Production Warning at Mana Gold Mine Seeking Alpha · November 12, 2026, 16:48 UTC
Stellantis CEO Warns of Multi-Billion Euro Impact from Chip Shortages and Raw Material Costs Seeking Alpha · November 12, 2026, 16:44 UTC
UBS Upgrades Rivian to Buy Rating Amid R2 Potential Motley Fool · November 12, 2026, 16:45 UTC
Stifel Downgrades EVgo to Hold Amid Weakening Growth Outlook Seeking Alpha · November 12, 2026, 16:41 UTC
Rowan Digital Infrastructure Secures Over $1.5 Billion in New Financing Seeking Alpha · November 12, 2026, 16:42 UTC
CAE Reports Q2 2027 Results with Increased EPS Guidance and Strong Defense Growth Motley Fool · November 12, 2026, 16:39 UTC
Alvotech Reports Q3 2026 Financial Results Amid Manufacturing Recovery Motley Fool · November 12, 2026, 16:39 UTC
Jacobs Solutions Declares Quarterly Dividend of $0.36 Per Share Seeking Alpha · November 12, 2026, 16:39 UTC
SOLV Energy Raises Revenue Guidance Following Record Q3 Project Execution Seeking Alpha · November 12, 2026, 16:40 UTC